Expression and activity of glycosylphosphatidylinositol-specific phospholipase d mRNA in bone marrow mononuclear cells isolated from patient with acute myeloid leukemia and their significance.
- Author:
Guang-Fen XIAO
1
;
Xue-Yuan TANG
;
Xin LI
;
Can ZENG
Author Information
1. Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan Province, China. xgftjx2003@yahoo.con.cn
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Bone Marrow Cells;
cytology;
metabolism;
Case-Control Studies;
Child;
Female;
Humans;
Leukemia, Myeloid, Acute;
metabolism;
pathology;
Male;
Middle Aged;
Phospholipase D;
genetics;
metabolism;
RNA, Messenger;
genetics;
Young Adult
- From:
Journal of Experimental Hematology
2010;18(1):15-18
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the expression and significance of glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) in bone marrow mononuclear cells (BMMNC) isolated from patients with acute myeloid leukemia (AML), GPI-PLD activity in BMMNC isolated from 78 patients with AML and 15 normal persons was measured by using GPI-anchored placental alkaline phosphatase (PLAP) as a substrate and Triton X-114 phase partitioning. The GPI-PLD mRNA expression was measured by semi-quantitive reverse transcription-polymerase chain reaction (RT-PCR). The results showed that the mRNA expression level and activity of GPI-PLD in BMMNC from de novo AML patients were 1.86 +/- 0.32 and 46.96 +/- 7.15% respectively; the mRNA expression level and activity of GPI-PLD in BMMNC from completely remission and refractory or relapsed patients were 1.26 +/- 0.29, 33.36 +/- 5.13%and 1.79 +/- 0.19, 44.31 +/- 7.22%, while those in BMMNC from normal controls were 1.27 +/- 0.23, 35.38 +/- 5.15% respectively. The mRNA expression level and activity of GPI-PLD in de novo and refractory or relapsed patients were obviously higher than those in normal controls with significant difference (p < 0.01), while the comparison between remitted patients and normal controls showed no statistical difference (p > 0.05). It is concluded that the expression level of GPI-PLD mRNA coincides with GPI-PLD activity. The mRNA expression and activity of GPI-PLD in de novo and refractory or relapsed patients are obviously higher than those in normal controls. It is worthy of further exploring whether GPI-PLD plays a certain role in process of leukemia pathogenesis.
